Indian biologists have made a significant breakthrough in oral cancer treatment by identifying genetic markers that can predict patient responses to immunotherapy. This research, led by scientists from various institutions including Yenepoya University and Tata Memorial Hospital, focuses on gingivo-buccal oral cancer, which is prevalent in India and primarily affects males. By analyzing cancer tissues from 72 patients, the researchers discovered that variations in gene expression could categorize patients into two distinct biological groups. They identified three specific genes—CD226, CD38, and KBTBD8—that could help predict immunotherapy responses in 86% of cases. The team aims to develop a low-cost diagnostic tool to assist clinicians in identifying patients who would benefit most from immunotherapy. Given that India has the highest burden of oral cancer globally, with more than 30% of cases and a significant mortality rate, this research is crucial for improving treatment outcomes. The findings were published in the journal Molecular Medicine, emphasizing the need for further validation through clinical trials.